EP0669939A1 - Somatotropin modifications - Google Patents
Somatotropin modificationsInfo
- Publication number
- EP0669939A1 EP0669939A1 EP93922424A EP93922424A EP0669939A1 EP 0669939 A1 EP0669939 A1 EP 0669939A1 EP 93922424 A EP93922424 A EP 93922424A EP 93922424 A EP93922424 A EP 93922424A EP 0669939 A1 EP0669939 A1 EP 0669939A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- replacing
- somatotropin
- serine
- asparagine
- glutamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 122
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 122
- 238000012986 modification Methods 0.000 title abstract description 19
- 230000004048 modification Effects 0.000 title abstract description 18
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 57
- 239000004220 glutamic acid Substances 0.000 claims abstract description 57
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 56
- 238000006467 substitution reaction Methods 0.000 claims abstract description 48
- 241001465754 Metazoa Species 0.000 claims abstract description 41
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 27
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000004475 Arginine Chemical group 0.000 claims abstract description 25
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 25
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 25
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 23
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 102220266317 rs1554949765 Human genes 0.000 claims abstract description 17
- 102220190959 rs577182758 Human genes 0.000 claims abstract description 17
- 241000283690 Bos taurus Species 0.000 claims abstract description 16
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims abstract description 10
- 235000013336 milk Nutrition 0.000 claims abstract description 6
- 239000008267 milk Substances 0.000 claims abstract description 6
- 210000004080 milk Anatomy 0.000 claims abstract description 6
- 235000004400 serine Nutrition 0.000 claims description 71
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 69
- 235000001014 amino acid Nutrition 0.000 claims description 66
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 53
- 235000009582 asparagine Nutrition 0.000 claims description 53
- 229960001230 asparagine Drugs 0.000 claims description 53
- 150000001413 amino acids Chemical group 0.000 claims description 45
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 38
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 36
- 235000004279 alanine Nutrition 0.000 claims description 36
- 239000004471 Glycine Substances 0.000 claims description 29
- 235000005772 leucine Nutrition 0.000 claims description 27
- 235000004554 glutamine Nutrition 0.000 claims description 26
- 102220212766 rs1060500017 Human genes 0.000 claims description 26
- 235000006109 methionine Nutrition 0.000 claims description 25
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 24
- 235000009697 arginine Nutrition 0.000 claims description 24
- 229930182817 methionine Natural products 0.000 claims description 24
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 23
- 235000014304 histidine Nutrition 0.000 claims description 23
- 235000013930 proline Nutrition 0.000 claims description 23
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 22
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 22
- 235000003704 aspartic acid Nutrition 0.000 claims description 22
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 22
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 22
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 19
- 239000004473 Threonine Substances 0.000 claims description 19
- 235000008521 threonine Nutrition 0.000 claims description 19
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 18
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 17
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 17
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 17
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 14
- 102200019600 rs281875323 Human genes 0.000 claims description 12
- 241000700159 Rattus Species 0.000 claims description 11
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 10
- 102200016464 rs104894278 Human genes 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- 239000004474 valine Substances 0.000 claims description 9
- 108010006025 bovine growth hormone Proteins 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 102220005263 rs33948578 Human genes 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 102100023097 Protein S100-A1 Human genes 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 7
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 7
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 2
- 241000283073 Equus caballus Species 0.000 claims 2
- 241001494479 Pecora Species 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 81
- 102000004169 proteins and genes Human genes 0.000 abstract description 70
- 235000018102 proteins Nutrition 0.000 abstract description 69
- 239000000126 substance Substances 0.000 abstract description 23
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 12
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract description 12
- 241000282887 Suidae Species 0.000 abstract description 8
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 5
- 238000002741 site-directed mutagenesis Methods 0.000 abstract description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract description 4
- 230000004075 alteration Effects 0.000 abstract 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 43
- 229940024606 amino acid Drugs 0.000 description 40
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 27
- 239000002585 base Substances 0.000 description 27
- 239000002773 nucleotide Substances 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 239000003111 growth hormone derivative Substances 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 241000894007 species Species 0.000 description 17
- 239000000872 buffer Substances 0.000 description 15
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 239000004472 Lysine Substances 0.000 description 10
- 235000018977 lysine Nutrition 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000122 growth hormone Substances 0.000 description 6
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 230000006240 deamidation Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 231100000219 mutagenic Toxicity 0.000 description 5
- 230000003505 mutagenic effect Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006652 catabolic pathway Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003398 denaturant Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220177976 rs751781798 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- GHUBZYXDFSBGLI-UHFFFAOYSA-N 1-[[(2,3-dimethoxyphenyl)-diphenylmethoxy]-diphenylmethyl]-2,3-dimethoxybenzene Chemical compound COC1=CC=CC(C(OC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C(=C(OC)C=CC=2)OC)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1OC GHUBZYXDFSBGLI-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101710085030 Gene 32 protein Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011188 deamidation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000006642 detritylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003370 dye binding method Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 150000002307 glutamic acids Chemical group 0.000 description 1
- 150000002309 glutamines Chemical class 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002614 leucines Chemical group 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002742 methionines Chemical group 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- -1 nucleotide phosphoramidite Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007243 oxidative cyclization reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 101150002764 purA gene Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000007921 solubility assay Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention provides novel single- or multiple-site substitution analogs of somatotropins that display enhanced stability relative to the unmodified protein.
- Somatotropin also referred to as St or growth hormone (GH) was originally discovered in pituitary gland extracts from various animal species. These proteins are single chain molecules containing about 200 amino acids and two intramolecular disulfide bonds. Since these proteins contain no carbohydrate, lipid or other cofactors, their molecular weight is approximately 22,000 daltons. A number of mammalian, avian, and aquatic somatotropins have been well characterized with respect to their structure and biological behavior (see for example, J.L. Kostyo & A.E. Wilhemi, Metabolism 25:105-124 (1976); O.G.P. Isaksson, et al, Ann. Rev. Physiol.
- Mammalian somatotropins are conserved molecules and similarities in amino acid sequences and protein structure are found between different species of animals.
- conformational stability The ability of a protein to maintain this tertiary structure is referred to as conformational stability. Often, the latter structure is essential for maintaining biological activity. In these cases, loss of tertiary structure is a form of protein degradation. Further, chemical and conformational stability of a protein are interrelated. That is, reactions that modify the covalent structure of proteins can affect conformational stability, and structural changes that alter conformational stability can affect the rate of chemical degradation, often in an adverse manner.
- somatotropins A number of chemical and conformational degradation pathways have been identified for somatotropins. For example, deamidation, hydrolysis, and rearrangement reactions of the carboxamide sidechain of asparagine have been observed at positions 13, 47, 140, and 148 (C. Secchi, et al., Int. J. Peptide Protein Res. 28: 298 (1986), at positions 99 (International publication WO 87/01708), and position 129 (Wood, D.C., et al., J. Biol. Chem. 264:14741 (1989)), of the highly homologous animal somatotropins.
- Methionines at positions 5, 124, 149, and 179 have been shown to oxidize to the corresponding sulfoxide (O. Cascone, et al.. Int. J. Peptide Protein Res. 16:299-305 (1980)).
- treatment of the protein with alkali under favorable conditions leads to intermolecular disulfide bridges generating reducible dimers.
- cysteines of the short loop positions 181 and 189.
- Conditions that lead to the loss of tertiary structure have also been defined. Denaturation of somatotropin occurs as a result of treatment with pH, guanidinium chloride, urea, and heat.
- partially denatured somatotropin has been shown to form a non- bioactive, poorly soluble aggregate species (D.N. Brems, Biochemistry 27:4541-4546 (1988)).
- modified forms of somatotropin that selectively stabilize the protein by minimizing individual degradation pathways while maintaining bioactivity in the target animal.
- These compounds are obtained by using site-directed modifications to generate nucleic acid substitutions in a somatotropin cDNA.
- the modified cDNA is then transformed into a host organism and the modified somatotropin analog expressed and purified.
- site-directed as used here is the process of controlled modifications of the primary structure of somatotropin. Single-site modifications are changes in the somatotropin gene sequence that produce one to three amino acid residue substitutions within a short segment of somatotropin.
- Single-site substitution analogs are designed to address a specific degradation pathway (e.g., deamidation of asparagine at position 47).
- Multiple-site substitution analogs combine two or more single-site substitutions into somatotropin in order to further stabilize the protein.
- Site-directed modifications enhance St stability either by directly eliminating functional groups that undergo chemical degradation, or by reinforcing the conformational stability of native tertiary structure.
- somatotropin analogs A number of variant or modified somatotropins, also referred to as somatotropin analogs, are known. For example:
- EP publication 0 355 460 and International publications WO 92/01789 and WO 90/02758 also report modified somatotropins by substitution of cysteine residues.
- International publication WO 90/08164 discloses somatotropins displaying enhanced stability by replacement of the asparagine residue at position 99 of bovine somatotropin.
- FIG. 1 shows the results of accelerated stability studies of rpSt and modified rpSt analyzed by RP-HPLC. Together with data of Figures 2-8, this data shows that standard protein analysis is not sufficiently sensitive to permit the identification of specific stability enhancement. Peak area (as a percentage of initial peak area) is plotted as a function of time. Somatotropins are dissolved in sodium carbonate buffer, pH 9.8 and incubated at 30°C for up to 30 days for these analyses. rpSt (o); A48P (D); F103E ( ⁇ ); C181.189S (v); N99S (•) ⁇ Further details are described in the Detailed Description section.
- Figure 2 shows tryptic maps of native rpSt (top) and following 30 days of decomposition (bottom) in alkaline buffers. Peaks are identified using LC-MS (LC-MS: liquid chromatography-mass spectrometry). The numbers correspond to individual tryptic fragments of native rpSt and are identified in Table IV. Individual degradation products, labelled in Figure 2 (bottom) are identified in Table V. This approach therefore permits a more detailed and sensitive assessment of chemical stability.
- Figure 3 shows a tryptic map of M5S following exposure to alkali buffers. This modified form of pSt is incubated as described in Figure 1. Samples are analyzed by tryptic mapping as described by J.J.Dougherty, et al. (Analytical Biochemistry 190:7-20 (1990)). In brief, this procedure calls for the incubation of somatotropin with trypsin at pH 8.3 at 5°C for 24 hours. The digests are mapped by HPLC. Additional details are described in the Detailed Description section.
- Figure 4 shows a tryptic map of N47D following exposure to aqueous alkaline.
- Figure 5 shows a tryptic map of A48P following exposure to alkaline buffers. Incubation and analyses are briefly described in the legends of Figures 1 and 3, respectively.
- Figure 6 shows a tryptic map of N99S following exposure to alkaline buffers. Incubation and analyses are briefly described in the legends of Figures 1 and 3, respectively.
- Figure 7 shows a tryptic map of C181,189S following exposure to alkaline buffers. Incubation and analyses are briefly described in the legends of Figures 1 and 3, respectively.
- This invention relates to modified somatotropins, or somatotropin analogs, having one or more amino acid changes that enhance the chemical and conformational stability of the protein while maintaining levels of bioactivity which are the same as, or similar to, the native protein.
- a first aspect of the invention relates to somatotropin analogs wherein one of the following single-site substitutions is made in the protein: serine replacing methionine at amino acid position 5 (the analog designated M5S), serine replacing asparagine at position 13 (N13S), leucine for the valine found at amino acid position 15 (V15L), histidine replacing glutamine at position 19, and arginine replacing histidine at position 20 (Q19H,H20R), glutamic acid replacing glycine at position 40 (G40E), aspartic acid replacing asparagine at position 47 (N47D), proline replacing alanine at position 48 (A48P), glutamic acid replacing phenylalanine at position 52 (F52E), asparagine replacing glycine at position 63 (G63N), phenylalanine replacing tryptophan at position 86 (W86F), glutamic acid replacing glycine at position 88 (G88E), alanine replacing threonine at position 98
- the invention relates to analogs of porcine or bovine somatotropin, most particularly porcine, having one of the substitutions listed above.
- a second aspect of the invention relates to multiple-site somatotropin analogs wherein two or more of the following single-site substitutions is made in the protein: serine replacing methionine at amino acid position 5 (M5S), serine replacing asparagine at position 13 (N13S), leucine replacing valine at position 15 (V15L), histidine replacing glutamine at position 19, and arginine replacing histidine at position 20 (Q19H,H20R), glutamic acid replacing glycine at position 40 (G40E), aspartic acid replacing asparagine at position 47 (N47D), proline replacing alanine at position 48 (A48P), glutamic acid replacing phenylalanine at position 52 (F52E), asparagine replacing glycine at position 63 (G63N), phenylalanine replacing tryptophan at position 86 (W86F), glutamic acid replacing glycine at position 88 (G88E), alanine replacing threonine at position 98, se
- this aspect of the invention relates to somatotropin analogs wherein the following multiple-site substitutions are made in the somatotropin protein: (a) V15L, A48P, F52E;
- the invention relates to analogs of porcine or bovine somatotropin, most particularly porcine, having the multiple-site substitutions listed above.
- An additional aspect of the invention also relates to expression plasmids comprising cDNA encoding one of the somatotropin analogs of the invention.
- a third aspect of the invention relates to host cells transformed with expression plasmids comprising cDNA encoding a porcine or bovine somatotropin of the invention.
- Additional aspects of the invention relate to a method of increasing the growth of an animal, a method for increasing milk production in a cow, and a method for increasing lean-to- fat ratio in a pig, each of the methods of the invention comprising administering to the animal an effective amount of a somatotropin analog having single-site or multiple-site amino acid substitutions as described above.
- one method of the invention comprises administering to an animal an effective amount of a somatotropin having one of the following single-site substitutions in the amino acid sequence of the protein: serine replacing methionine at amino acid position 5 (the analog designated M5S), serine replacing asparagine at position 13 (N13S), leucine for the valine found at amino acid position 15 (V15L), histidine replacing glutamine at position 19, and arginine replacing histidine at position 20 (Q19H,H20R), glutamic acid replacing glycine at position 40 (G40E), aspartic acid replacing asparagine at position 47 (N47D), proline replacing alanine at position 48 (A48P), glutamic acid replacing phenylalanine at position 52 (F52E), asparagine replacing glycine at position 63 (G63N), phenylalanine replacing tryptophan at position 86 (W86F), glutamic acid replacing glycine at position 88 (G88E), alanine
- An additional method of the invention comprises administering to the animal an effective amount of a multiple-site somatotropin having two or more of the following: serine replacing methionine at amino acid position 5 (designated M5S), serine replacing asparagine at position 13 (N13S), leucine replacing valine at position 15 (V15L), histidine replacing glutamine at position 19, and arginine replacing histidine at position 20 (Q19H.H20R), glutamic acid replacing glycine at position 40 (G40E), aspartic acid replacing asparagine at position 47 (N47D), proline replacing alanine at position 48 (A48P), glutamic acid replacing phenylalanine at position 52 (F52E), asparagine replacing glycine at position 63 (G63N), phenylalanine replacing tryptophan at position 86 (W86F), glutamic acid replacing glycine at position 88 (G88E), serine replacing asparagine at position 99 (N99S), alan
- this aspect of the method of the invention comprises administering to the animal an effective amount of a somatotropin having multiple-site substitutions selected from the group consisting of (a) V15L, A48P, F52E; (b) A48P, N99S, CI8I,189S; (c) F52E, G88E, F103E, I137E; (d) V15L, Q19H.H20R, A48P, F52E; (e) N13S, W86F, Q140S, N148S, M124L, M179L; and (f) V15L, A48P, F52E, N99S, F103E, C181.189S.
- a somatotropin having multiple-site substitutions selected from the group consisting of (a) V15L, A48P, F52E; (b) A48P, N99S, CI8I,189S; (c) F52E, G88E, F103E, I137E; (d) V15L, Q
- the present invention discloses somatotropin modifications that display enhanced conformational and chemical stability as compared to native pituitary or recombinantly derived somatotropins.
- Single site modifications meeting this criteria include, for example, M5S, V15L, Q19H,H20R, A48P, G40E, N47D, F52E, G88E, F103E, I137E, and R125S.
- Additional modifi ⁇ cations meeting this criteria and included as multiple-site analogs include, for example, N99S, Cl 81.189S. This shorthand notation shows, for example, that in M5S, methionine at position 5 of the rpSt primary structure, is replaced by serine.
- Sequence ID: 1 shows the primary structure of pSt as isolated from pigs.
- Other closely related somatotropin molecules having pSt activity have also been identified due to genetic polymorphism. Because of these changes and the slightly altered structure of homologous somatotropins, minor changes in the numbering and specific residues in the primary structure are found in the literature. The identity of specific protein modifications that enhance somatotropin stability have been made by characterizing single-site and multiple-site amino acid substitution somatotropins in chemical and bioactivity studies.
- the strategies used to enhance the overall stability of the protein include: (i) modifications of somatotropin primary structure to enhance conformational stability of the protein, and/or (ii) specific elimination of somatotropin residues that are known to be involved in the decomposition of the protein, and/or (iii) modifications of somatotropin primary structure that permit the protein to be handled in neutral aqueous media.
- This strategy can also result in an indirect stabilization of protein since it can now be processed, stored, and formulated under conditions that will have a much lower propensity for decomposing somatotropins.
- Suitable amino acid substitutions which will remove this decomposition site and enhance solubility of the protein are serine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, proline, and threonine.
- Suitable amino acid substitutions which will remove this hydrolytic degradation site are serine, glutamic acid, threonine, glutamine, aspartic acid, lysine, arginine, alanine, and histidine.
- Suitable amino acid substitutions which will remove the conformational flexibility of the backbone include tyrosine, proline, threonine, serine, glutamic acid, asparagine, glutamine, aspartic acid, lysine, and arginine.
- Suitable amino acid substitutions which will enhance the aqueous solubility of the protein are glutamic acid, alanine, glycine, tyrosine, proline, threonine, serine, histidine, asparagine, glutamine, aspartic acid, lysine, and arginine.
- Suitable amino acids substitutions which will enhance the conformational stability of the protein backbone include asparagine, arginine, lysine, aspartic acid, glutamine, glutamic acid, histidine, serine, threonine, proline, tyrosine, and alanine.
- Suitable amino acids substitutions which will remove this degradation site without substantively enhancing the hydrophilicity of the protein interior include phenylalanine, tyrosine, leucine, isoleucine, and valine.
- Suitable amino acids which are expected to elimante secondary decomposition reactions near residue 99 while maintaining overall solubility of the protein include alanine, proline, glycine, glutamic acid, aspartic acid, lysine, and arginine.
- Suitable amino acids which are expected to elimante secondary decomposition reactions near residue 99 while maintaining overall solubility of the protein include alanine, proline, glycine, glutamic acid, aspartic acid, lysine, and arginine.
- Suitable amino acid substitutions which will enhance the aqueous solubility of the protein include glutamic acid, alanine, glycine, tyrosine, proline, threonine, serine, histidine, asparagine, glutamine, asparatic acid, lysine, and arginine.
- Suitable amino acids which will eliminate the oxidative degradation of this residue include leucine, arginine, asparagine. aspartic acid, glutamic acid, glutamine, proline, serine, and threonine. Replacing arginine at position 125 with serine is also known to enhance the stability of the molecule.
- Suitable amino acid substitutions which will enhance the aqueous solubility of rpSt include glutamic acid, alanine, glycine, tyrosine, proline, threonine, serine, histidine, asparagine, glutamine, aspartic acid, lysine, and arginine.
- modified somatotropins of the invention are first characterized by means of the chemical and conformational studies described in more detail below.
- a somatotropin generally exhibits an enhancement (as compared to the native somatotropin) in one of the stability or conformational studies described herein. It is contemplated that some degree of decreased bioactivity is acceptable due, in part, to the advantage gained by enhanced stability. Preferred modifications enhance both chemical and/or conformational stability as well as bioactivity in the host species.
- Site-directed mutagenesis is a technique well known in the art of recombinant technology.
- Several techniques for site-directed mutagenesis have been developed for introducing specific changes in a DNA sequence and may be used to produce the compounds of the instant invention (Kramer, E.,W, et al, Nucl. Acids Res. 12:9441-56 (1984); Mandecki, W., PNAS USA, 83:7177-81 (1986); Zollar, M.J. and Smith, M., Nucl. Acids Res.
- One of the variations is to use a longer mutagenic oligonucleotide (about 40 bases) in the mutagenesis reaction and to screen candidates using a shorter oligonucleotide ( ⁇ 20 bases).
- the other variation in the protocol is to transform the mutagenic reaction into either BHM71-18 mutS::TnlO or BST-lc, pool the colonies by scraping the colonies together, isolating vector DNA and re-transforming into either BST-lc or MCI 061. Electroporation is used when the initial transformation yields are low. Procedures leading to the MC1061 and BST-lc culture systems are described detail in International publication W088/06186. BST-IC is available from the Agricultural Research Service Culture Collection in the Northern Regional Research Center.
- MC1061 is purchased from Clontech Laboratories, Inc., Palo Alto, CA.
- BHM71-18 mutS::TnlQ is purchased from Boehringer Mannheim Biochemicals, Indianapolis, IN, as a part of a Site-Directed Mutagenesis Kit (Cat. No. 1027-492). It is apparent to those skilled in the art that due to the degeneracy of the genetic code that other triplets (coding for the same amino acids) may be substituted in the primers used to make the modified somatotropins of the invention.
- the porcine somatotropin gene (PStl) used in these studies is isolated from a porcine pituitary cDNA library constructed at the Upjohn Company and is described in International publication WO 88/06186.
- the pURA plasmid, used for expression of the pSt gene, is described in International publication WO 88/06186.
- the vector is modified to contain the Serratia marcescens trg promoter as described in WO 90/05186 and the ConSD ribosome- binding site as described by Curry and Tomich supra.
- the E. coli strain and preferred host for expression of the somatotropin analogs of the invention is BST-lc.
- Transformed cells containing the modified porcine gene are grown at the 10 liter scale. After fermentation the cell are centrifuged, and the modified porcine somatotropins are isolated using a bench scale modification of procedures described International publication WO 87/00204.
- somatotropin analog is verified by use of a quantitative tryptic map (J.J. Dougherty, et al, Analytical Biochemistry 190:7-20 (1990)).
- the trypsin used in these studies is previously treated with TPCK (l-tosylamide-2-phenylethyl chloromethyl ketone) in order to irreversibly inhibit chymotrypsin that may contaminate the product (Worthington Biochemical, Freehold, NJ.).
- TPCK l-tosylamide-2-phenylethyl chloromethyl ketone
- Buffers for chromatography are: A - 0.1% TFA in water; B - 70% CH 3 CN/0.07%TFA. Following injection, the column is eluted for 5 minutes in 1% B and chromatographed using a gradient of 1% B to 64.3% B in 120 minutes. Flow rate is 1.2 ml/min. The column effluent is monitored at 214 nm with column temperature at 40°C. Because of the reproducibility of the elution profile and the resolving capacity of the HPLC analysis, it is generally easy to separate and isolate any tryptic fragments that differ in retention time from those derived from wild-type somatotropins.
- the peptide sequence of this region can be confirmed either by mass spectrometry or by NH 2 -terminal sequence analysis. Protein purity is determined using RP-and SEC-HPLC, and isoelectric focusing. These techniques are well known by those skilled in the art.
- Somatotropin concentrations are determined by the absorbance at 278 nm using an extinction coefficient of 15,270 M '1 (Burger, H.G., et al, J. Biol. Chem. 241:449-457 (1966)). Determination of Relative Conformational Stability
- sample dilutions to the appropriate concentrations of protein and denaturant are made using the stock solution buffer and 8.0 M guanidine HC1.
- the stock denaturant and buffer solutions are filtered through 0.45 ⁇ m disposable filters (Coming Inc., Coming, N.Y.) prior to use. Both the stock solutions and prepared samples are stored at 4°C. Before spectral analysis, samples are allowed to equilibrate at ambient temperature for several hours. Protein concentrations are determined using a dye- binding method (bicinchoninic acid) This method is described by Smith, P. et al., Anal. Biochem.
- Fluorescence measurements are performed on a photon-counting spectrofluorimeter (SLM Instruments, Inc., Urbana, IL). Spectra are obtained after excitation at 295 nm by monitoring protein emission at 355 nm. 2 nd derivative UV absorption measurements are performed on scanning (Aviv Associates, Lakewood, N.J.) and diode-array spectrometers (Hewlett Packard Scientific Instruments, Palo Alto, CA). Absorption spectra are obtained between 280 and 300 nm. Subsequent data handling is performed using algorithms supplied with each vendor's software.
- Circular dichroic (CD) measurements are performed on (JASCO 500C and 700 series spectropolarimeters (Japan Spectroscopic Company, Tokyo, Japan). Near UV (275 to 325 nm) and far UV (226 to 218 nm) data are obtained for analysis.
- Raw data from this technique obtained in units of ellipticity (millidegrees), is expressed in units of mean residue ellipticity (deg»cm 2 /dmol) using the equation:
- Somatotropins (2 mg/ml) are dissolved in 0.05M sodium carbonate, pH 9.8. The vials are capped, placed in an oven and incubated at 30°C for up to 30 days. Daily aliquots are taken and stored at -20°C prior to analysis. Aliquots (20 ⁇ l) are analyzed using twin pump reverse phase-HPLC with UV detection
- Tryptic mapping is performed as described above. Determination of Relative Solubility Proteins are dissolved in 0.05M sodium carbonate pH 9.8, at a protein concentration of 50mg/ml. The pH is adjusted with 50% NaOH where necessary. After filtration, a 250ul aliquot is withdrawn for dialysis. Microdialysis is conducted in a low volume chamber, fitted with a dialysis membrane (6000-8000 molecular weight cutoff). The unit is connected to a reservoir containing 1 liter of 0.05M sodium carbonate pH 9.8. In addition, a second unit is attached to a reservoir containing 0.04M sodium phosphate pH 7.0.
- a Minipuls 2 peristaltic pump (Gilson, Middleton, WI) is used to pump buffer through the dialysis units at a flow rate of 30ml/hr. Samples are dialyzed for 20 hours at 5°C. The dialyzed samples as well as the starting material are then centrifuged at 13,000 rpm for 6 minutes in an Eppendorf 5415 centrifuge (Brinkman Instruments, Des Plaines, EL). The protein concentration of the supematant liquid is determined using the BCA assay (Pierce Chemical Company, Rockford, IL; P.K. Smith, et al, Anal. Biochem. 150:76-85 (1985)). Determination of Relative Bioactivity
- the compounds of the invention may be tested for bioactivity by measuring growth in hypophysectomized rats and the target species following repeated administration.
- the hypophysectomized rat growth assay is generally recognized by those skilled in the art as an appropriate method for obtaining a relatively rapid measure of the relative potency of somatotropins.
- the modified somatotropins of the present invention are screened using hypophysectomized rats following the procedure of Evans, H.M. and Long J.A., Anat. Rec. 21:61 (1921), and M.D. Groesbeck and A.F. Parlow, Endocrinology 120:2582-2590 (1987), as modified below. Briefly, linearity of the assay is determined via the subcutaneously injection of eight hypophysectomized rats with somatotropin at doses of 2, 10, 50, and 250 ⁇ g/rat-day.
- the modified somatotropins are tested at 15 and 60 ⁇ g/ml.
- the weight of the rats are measured daily on the first day and up to the day following die final injection.
- Relative increases in total body weight are recorded using various modified somatotropins of the invention with the native form of the molecule, either natural somatotropin and/or recombinant somatotropin, serving as a positive control.
- bioactivity of the modified somatotropins of the invention can be measured using the swine growth assay using Yorkshire pigs. In this procedure, 48 gilts and barrows are sorted according to weight, and randomly assigned to four blocks of 6 pens each. Each pen contained 2 gilts and 2 barrows. Treatment was assigned randomly to pens within a block.
- the animals are left for a 7 day acclimation. They are then injected with somatotropin or modified somatotropin at a rate of 60 ⁇ g/kg/d for 14 days. Positive controls are administered recombinant rpSt. The pretreatment weight is compared with posttreatment weight with measurements at days 1, 15, and 22 of the experiment.
- the compounds of the invention can be used to enhance growth characteristics in the species in which the native somatotropin has been shown to have growth-related bioactivity.
- growth hormones are very similar in their amino acid sequences, hormones originating from one species may enhance the growth of other animal species that evolved at earlier times.
- the compoimds of the invention are suitable for use in this manner as well.
- somatotropins of less highly evolved species, such as cattle and pigs have not been found to be functional in more highly evolved species, such as humans.
- Admimstration of the compounds of the invention into animals is done according to known methods using any route effective to deliver the required dosage to the animal's circulatory system. Modes of administration include those typically encoimtered for the species of choice.
- the effective dosage range depends on the animal, as well as the age. weight, and general health of the animal to be treated. These and other parameters which are needed to determine the effective dosage range for a given species is well within the purview of one skilled in the art. For instance, in bovine the effective amount is in the range of 1.0 to 200 milligrams per animal per day. In pigs, for instance the effective amount is about 60 ⁇ g/kg/d.
- the potential commercial use of the compounds of the invention in non-human animals derives from their enhancement of the animal's metabolism.
- administration of an effective amount of the porcine analogs of the invention allows a pig to grow leaner in a shorter time span and requires less feed to do so.
- administration of an effective amount of the bovine analogs of the invention allows milk producing animals, such as dairy cattle, to produce more milk for the same or lower amount of feed.
- the compounds of the invention are identified using a letter-number-letter string which designates the location of the substitution and the native and substituted amino acid.
- the letters of this string follow the accepted single letter designation for amino acids.
- the single letter designation and the amino acid to which it corresponds are shown in Chart 1.
- the first letter (X ⁇ ) designates the native amino acid found in wild-type somatotropin;
- the second letter ( ⁇ X) designates the amino acid that is substituted in the analog.
- the number (-0-) represents the sequential location of the amino acid in the native porcine somatotropin.
- V15L designates a somatotropin analog of the invention where leucine is substituted for the valine residue found at position 15 of native porcine somatotropin
- A48P designates the somatotropin analog of the invention having proline substituted for alanine at position 48 of the native porcine somatotropin.
- an “effective amount” is the amount of a modified somatotropin of the invention which results in the desired biological effect in the target animal.
- Effective amount includes the dosage level which is efficacious as well as the period of time such a dose is administered to attain or maintain the efficacious dose.
- Microorganism means both single cellular prokaryotic and eukaryotic organisms such as bacteria, yeast, actinomycetes and single cells from higher plants and animals grown in cell culture.
- Single-site means single or multiple changes in the somatotropin gene sequence which result in a one to three amino acid residue substitution within a short segment of the somatotropin protein.
- the analogs A48P and Q19H.H20R designate single- site substitutions.
- Multiple-site substitutions or analogs combine two or more single-site substitutions into an individual protein in order to further enhance desirable characteristics.
- the analog V15L, A48P, F52E, N99S, F103E, C18U89S designates a multiple- site modified somatotropin.
- Native somatotropin refers to somatotropins having amino acid sequences which are the same as the naturally-occurring forms of the molecule.
- Native somatotropins may be derived from either natural or recombinant sources. Due to the molecular heterogeneity of somatotropins, the position numbers of amino acid residues of the various somatotropins may differ. The term native somatotropin includes these naturally occurring species. Sequence ID: 1 illustrates one species of porcine somatotropin (pSt). The numbering for other somatotropins may differ.
- Somatotropin or “St” means an animal somatotropin and includes somatotropins derived from either the pituitary gland tissue ("natural somatotropin”) or from microorganisms transformed by recombinant genetics to produce either naturally-occurring or modified forms of somatotropin ("recombinant somatotropin”).
- a specific mammalian source such as a somatotropin of porcine origin (porcine somatotropin or pSt)
- the somatotropin includes those derived from either pituitary sources or from transformed microorganisms.
- Example 1 Production of M5S.
- a site-directed mutagenic technique for double-stranded primer extension is used to introduce altered codons for methionine at amino acid position 5 in the PStl cDNA gene.
- the target sequence is cloned into a suitable plasmid and plasmid DNA is prepared.
- the plasmid DNA is denatured by treatment with NaOH which causes "nicks" in the DNA molecule deoxyribose-phosphate backbone. This relaxes the DNA and permits an oligomer containing the desired sequence changes to hybridize to the target site.
- the 3' end of the oligomer generates a primer for the DNA polymerase activity of the Polymerase A Klenow fragment which extends the primer, synthesizes a new DNA strand containing the mutagenic oligomer and displaces the normal complementary strand.
- the extension reaction increases the probability of the incorporation by genetic recombination.
- the DNA is transformed into competent cells and the resultant colonies are screened by colony filter hybridization. Plasmid DNA is isolated and sequenced from positive candidates.
- the oligomers used to construct the position 5 serine change in the Pstl gene are produced by techniques described in International publication WO 88/06186 and is shown in Sequence ID:2. An oligonucleotide so produced and set forth above contains the proper change.
- Example 2 Production of V15L Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID:3), a somatotropin analog having leucine at position 15 is also constructed.
- Example 3 Production of G40E Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID:4), a somatotropin analog having glutamic acid at position 40 is also constructed.
- Example 4 Production of N47D
- Example 5 Production of A48P Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID:6), a somatotropin analog having proline at position 48 is also constructed.
- Example 6 Production of F52E Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID:7), a somatotropin analog having glutamic acid at position 52 is also constructed.
- Example 7 Production of E56A Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID: 8), a somatotropin analog having alanine at position 56 is also constructed.
- Example 8 Production of G88E Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID:9), a somatotropin analog having glutamic acid at position 88 is also constructed.
- Example 9 Production of N99S
- Example 11 Production of R125S Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID: 12), a somatotropin analog having serine at position 125 is also constructed.
- Example 12 Production of I137E Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID: 13), a somatotropin analog having glutamic acid at position 137 is also constructed.
- Example 13 Production of Q19H,H20R Following the techniques of Example 1, but substituting the appropriate oligomers encoding die desired amino acids (as seen in Sequence ID: 14), a somatotropin analog having histidine at position 19 and an arginine at position 20 is also constructed.
- Example 14 Production of C 181 , 189S
- Example 16 Production of T98A,N99S,S100A Following the techniques of Example 1 , but substituting the appropriate oligomers encoding the desired amino acids (as seen in Sequence ID: 16), a somatotropin analog having alanine at position 98, serine at position 99, and alanine at position 100 is also constructed. Examples 17-22: Multiple-site modified somatotropins
- large DNA sequences can be constructed by combining long oligonucleotide synthesis with Polymerase Chain Reaction (PCR) as has been demonstrated by R.W. Barnett and H. Erfle, Nucleic Acid Research 18:3094 (1990), P.J. Dillon and CA. Rosen, Biotechniques 9:298-299 (1990), and R.M. Horton, et al, Gene 77:61-68 (1990).
- PCR Polymerase Chain Reaction
- An entire gene of porcine somatotropin can be constructed containing the desired codon changes using this approach.
- Two long oligonucleotides of about 200 bases is synthesized as described below (see, "Synthesis of Oligonucleotides").
- the concentration of the full length oligonucleotides is low due to the inefficiency in the addition of each nucleotide.
- These two oligonucleotides are designed to overlap by 20 to 30 bases, and when mixed together can be extended by a DNA polymerase to form a larger 400 base pair fragment. This fragment can be amplified using PCR. The fragment is then isolated, cut with restriction enzymes and cloned into an appropriate expression vector. By generating two or three sets of these fragments an entire porcine somatotropin gene can be constructed.
- Oligonucleotides are made by the phosphoramidite method for DNA synthesis.
- this process uses as the starting material the 5' dimethoxytrityl ether of a nucleoside bound to a silica support. This nucleoside will be the 3'-OH end of the product oligonucleotide.
- the first step is detritylation with acid.
- the nucleotide phosphoramidite to be added is activated.
- the addition step occurs in less than 3 minutes and is 95 to 97% complete. Any chains which did not undergo addition is capped by acetylation so that it will not react in subsequent steps.
- the intemucleotide linkage is then converted from the phosphite to the more stable phosphate by oxidation. This compound is detritylated and the cycle continues until the last nucleoside is added. At this point, the oligonucleotide is the bases A, G, and C The chain is then cleaved from the support with ammonium hydroxide. After, the solution containing the DNA is removed from the instrument, the protecting groups are cleaved by a 8-hour treatment with ammonium hydroxide at 55°C
- Example 17 Production of V15L, A48P, F52E, N99S, F103E, C181.189S Following the techniques described above, a somatotropin multiple-site analog having leucine at position 15, proline at position 48, glutamic acid at position 52, serine at position 99, glutamic acid at position 103, and serine residues at positions 181 and 189 is constructed.
- Example 18 V15L, A48P, F52E Following the techniques described above, a somatotropin multiple-site analog having leucine at position 15, proline at position 48, glutamic acid at position 52 is constructed.
- Example 19 A48P, N99S, C181J89S
- Example 20 F52E, G88E, F103E, I137E Following the techniques described above, a somatotropin multiple-site analog having glutamic acids at positions 52, 88, 103, and 137 is constructed.
- Example 21 V15L, Q19H, H20R, A48P, F52E Following the techniques described above, a somatotropin multiple-site analog having leucine at position 15, histidine at position 19, arginine at position 20, proline at position 48, and glutamic acid at position 52, is constructed.
- Example 22 N13S, W86F, Q140S, N148S, M124L, M179L Following the techniques described above, a somatotropin multiple-site analog having asparagine at position 13, phenylalanine at position 86, serines at positions 140 and 148, and leucines at positions 124, and 179 is constructed.
- Tables I, II, and III summarize the relative conformational stability of these rpSt analogs relative to wild-type proteins. As described earlier, conformational stability is compared by equilibrium denaturation using several distinct spectral probes. (For, i.e., second derivative UV absorption, circular dichromism and fluorescent spectroscopy). These experiments are plotted in order to obtain the denaturation midpoint of unfolding.
- the compounds of the invention are incubated in the presence of alkaline and peroxide-containing buffers in order to determine their relative susceptibility to these reagents.
- Alkaline buffers are used in these studies since they permit the observation of hydrolytic degradation reactions in a compressed time-frame.
- peroxide containing buffers permit the observation of oxidative degradative reactions in a compressed time-frame.
- aliquots are subjected to trypsin digestion.
- the tryptic fragments are separated and identified using a technique known as LC-MS. In this technique, fragments are sorted according to their affinity for reversed-phase HPLC and are then identified on the basis of their mass to charge (m/e) ratio.
- Table IV lists the porcine St fragments that are generated by digestion by trypsin and their respective molecular weights.
- Table V lists additional peaks that have been observed incubation of porcine St in the presence of alkaline buffers. An analog is said to have enhance chemical stability when one or more of the latter peaks do not form or form at a slower rate.
- Example 25 Characterization of enhanced solubility in aqueous buffers at neutral pH. The modified somatotropins are characterized to determine if the solubility of these compounds in neutral, aqueous buffers could be significantly altered by single-site amino acid substitutions. Wild-type and modified somatotropins are tested via dialysis as described in Detailed Description section. The results are shown in Table IV.
- Solubility enhancements can occur, for example, on substitution of hydrophobic amino acids with relatively hydrophilic amino acids.
- solubility can be enhanced by changing the isoelectric point of the protein. (The isoelectric point is the pH at which the protein has no net charge).
- Example 26 Rat growth bioassay.
- the rat growth assay shows that the modified porcine somatotropins of the invention have equivalent bioactivity as compared to the native protein. A summary of these results are shown in Table VII.
- Example 27 Porcine bioassay.
- Crossbred Yorkshire pigs were utilized for this bioassay. Forty-eight gilts and 48 barrows weighing approximately 50 kg were ranked by body weight (BW). These rank orders were used to divide each gender into 4 blocks. Within each gender and block, pigs were assigned randomly to one of 6 pens, avoiding littermate assignments to the same pen. Each pen contained 2 gilts and 2 barrows. Treatment was assigned randomly to pens within a block. Following assignment to pens, the pigs were allowed at least a 7 day acclimation period before initiation of the treatments.
- BW body weight
- figure 2 shows the retention times for these peaks.
- GGAGGGCATC CAGGCCCTGA TGCGGGAGCT GGAGGATGGC AGCCCCCGGG 400
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Fodder In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97109892A | 1992-10-28 | 1992-10-28 | |
US971098 | 1992-10-28 | ||
PCT/US1993/009232 WO1994010200A1 (en) | 1992-10-28 | 1993-10-04 | Somatotropin modifications |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0669939A1 true EP0669939A1 (en) | 1995-09-06 |
Family
ID=25517926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93922424A Ceased EP0669939A1 (en) | 1992-10-28 | 1993-10-04 | Somatotropin modifications |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0669939A1 (xx) |
JP (1) | JPH08502963A (xx) |
AU (1) | AU5142293A (xx) |
CA (1) | CA2145546A1 (xx) |
MX (1) | MX9306676A (xx) |
WO (1) | WO1994010200A1 (xx) |
ZA (1) | ZA936811B (xx) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9723955D0 (en) | 1997-11-14 | 1998-01-07 | Generic Biolog Limited | Improvements in or relating to detection of molecules in samples |
GB2375765B (en) * | 1997-11-14 | 2003-02-26 | Kymed Gb Ltd | Tagged growth hormone molecules |
US6844322B2 (en) | 2000-07-21 | 2005-01-18 | Monsanto Technology Llc | Method for induced lactation |
WO2010015668A1 (en) | 2008-08-06 | 2010-02-11 | Novo Nordisk A/S | Conjugated proteins with prolonged in vivo efficacy |
EP2389389B1 (en) | 2009-01-22 | 2015-04-15 | Novo Nordisk Health Care AG | Stable growth hormone compounds |
CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
CA2787890C (en) | 2010-01-22 | 2020-01-14 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
MX338357B (es) | 2010-01-22 | 2016-04-13 | Novo Nordisk Healthcare Ag | Compuestos estables de la hormona de crecimiento. |
PL2718316T3 (pl) * | 2011-06-10 | 2020-06-29 | Novo Nordisk A/S | Polipeptydy |
CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
WO2015070911A1 (en) * | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified kz144 endolysin sequence |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0355460B1 (en) * | 1988-08-24 | 2000-12-27 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization |
KR910700264A (ko) * | 1989-01-19 | 1991-03-14 | 로버트 에이. 아미테이지 | 소마토트로핀 유사물 |
CA2057035A1 (en) * | 1989-07-10 | 1991-01-11 | Sherwood R. Lehrman | Somatotropin analogs |
US5310882A (en) * | 1990-11-30 | 1994-05-10 | American Cyanamid Company | Somatotropins with alterations in the α-helix 3 region |
-
1993
- 1993-09-15 ZA ZA936811A patent/ZA936811B/xx unknown
- 1993-10-04 WO PCT/US1993/009232 patent/WO1994010200A1/en not_active Application Discontinuation
- 1993-10-04 JP JP6511061A patent/JPH08502963A/ja active Pending
- 1993-10-04 EP EP93922424A patent/EP0669939A1/en not_active Ceased
- 1993-10-04 CA CA002145546A patent/CA2145546A1/en not_active Abandoned
- 1993-10-04 AU AU51422/93A patent/AU5142293A/en not_active Abandoned
- 1993-10-27 MX MX9306676A patent/MX9306676A/es unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9410200A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU5142293A (en) | 1994-05-24 |
ZA936811B (en) | 1995-03-15 |
CA2145546A1 (en) | 1994-05-11 |
MX9306676A (es) | 1994-04-29 |
WO1994010200A1 (en) | 1994-05-11 |
JPH08502963A (ja) | 1996-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60038737T2 (de) | Modifiziertes cytokin für seine stabilizierung | |
US5350836A (en) | Growth hormone antagonists | |
KR0184235B1 (ko) | 거핵구 형성 인자 | |
KR920000849B1 (ko) | 생물학적으로 활성인 단백질의 제조방법 | |
AU634517B2 (en) | Somatotropin analogs | |
EP0669939A1 (en) | Somatotropin modifications | |
CN1197461A (zh) | 截短的神经胶质细胞系来源的神经营养因子 | |
CA2285673C (en) | Cyclic analogs of histatins | |
IE914154A1 (en) | Somatotropins with alterations in the alpha-helix 3 region,¹alpha-helix 2 region combinations thereof, and in¹combination with other mutations | |
AU639245B2 (en) | Somatotropin analogs | |
CA2056467C (en) | Somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations | |
WO1992019736A1 (en) | Growth hormone antagonists | |
US5663305A (en) | Somatotropin analogs | |
WO1988007084A1 (en) | Bovine growth hormone analogs | |
CA1277933C (en) | Porcine growth hormone analogs | |
US6465616B1 (en) | Interleukin-5 antagonist | |
EP0904293A1 (en) | An interleukin-5 antagonist | |
AU723413B2 (en) | An interleukin-5 antagonist | |
US7358338B2 (en) | Heme peptide | |
JPH03502758A (ja) | ポリペプチド類においてノルロイシン含有量を制御するための発酵培地および方法 | |
Skryabin et al. | Growth hormones: expression, structure and protein engineering | |
CA2216755A1 (en) | Peptides with growth promotion properties | |
DE19649233A1 (de) | Prozessierte Polypeptide mit IL-16 Aktivität, Verfahren zu ihrer Herstellung und Verwendung | |
JPH0259599A (ja) | 改良エリスロポイエチン組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950515 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19950818 |
|
RHK1 | Main classification (correction) |
Ipc: C07K 14/00 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PHARMACIA & UPJOHN COMPANY |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19970609 |